Market Watch column provides a thorough analysis of stock market fluctuations and expert ratings.

AbbVie Shares Surge 13.72% in Six Days as Rinvoq Secures FDA Approval for GCA Treatment Ranking 44th in Market Activity

Market BriefTuesday, Apr 29, 2025 7:40 pm ET

1min read

AbbVie (ABBV) shares rose 0.61% on April 29, 2025, marking the sixth consecutive day of gains, with a total increase of 13.72% over the past six days. The company's trading volume reached 11.90 billion, ranking 44th in the day's market activity.

AbbVie's Rinvoq (upadacitinib) has received U.S. FDA approval for the treatment of giant cell arteritis (GCA) in adults. This approval makes Rinvoq the first and only oral Janus Kinase (JAK) inhibitor available for this condition, which is also known as temporal arteritis. The approval was based on strong Phase 3 trial results and a significant year-over-year sales increase in the first quarter.

The FDA approval for Rinvoq includes a 15 mg daily dosage specifically for treating adults with GCA. The approval comes with warnings about serious infections and an increased risk of death in people aged 50 and above who have at least one cardiovascular risk factor.

This approval is a significant milestone for abbvie, as it expands the therapeutic indications for Rinvoq, which was previously approved for other inflammatory conditions. The company announced the approval on April 29, 2025, highlighting the potential for Rinvoq to become a blockbuster drug in the treatment of GCA.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.